SCHEMBL9762769

SCHEMBL9762769

NOC(=O)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TSHR P16473 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
MGLL Q99685 1/20 0.46
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
REN P00797 1/20 0.45
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44
NPC1 O15118 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2198859 0.82 ALOX5 (0.50) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4018145 0.80 LMNA (0.56) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL27364470 0.78 CCR6 (0.55) LMNAALDH1A1NPSR1TSHRKMT2A
SCHEMBL8060186 0.78 SRD5A1 (0.54) LMNAKDM4EALDH1A1NPSR1TSHR
SCHEMBL825414 0.78 LMNA (0.63) LMNAKDM4EALDH1A1NPSR1TSHR
Carbamic Acid SCHEMBL29254315 0.78 CCR6 (0.51) LMNAKDM4EALDH1A1NPSR1KMT2A
SCHEMBL9278775 0.77 ALDH1A1 (0.64) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL2182156 0.77 LMNA (0.49) LMNAKDM4EALDH1A1NPSR1TSHR
SCHEMBL2182432 0.77 LMNA (0.49) LMNAKDM4EALDH1A1NPSR1TSHR
SCHEMBL1386528 0.77 LMNA (0.57) LMNAKDM4EALDH1A1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102863374-A Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders ARYX THERAPEUTICS 2013-01-09 CN disclosed
CN-101258151-B Process for the synthesis of stereoisomeric compounds useful in the treatment of gastrointestinal and central nervous system disorders and intermediates ARYX THERAPEUTICS INC 2012-10-10 CN disclosed
CN-101258151-A Process for the synthesis of stereoisomeric compounds useful in the treatment of gastrointestinal and central nervous system disorders and intermediates ARYX THERAPEUTICS INC (US) 2008-09-03 CN disclosed
US-5057610-A Oxidation, heat and radiation resistance CIBA-GEIGY CORPORATION (US) 1991-10-15 US disclosed
EP-0244355-B1 COMPOSITIONS STABILIZED WITH SUBSTITUTED AMINOCARBAMATES, AND SUBSTITUTED AMINOCARBAMATES CIBA-GEIGY AG (CH) 1990-08-01 EP disclosed
US-4758614-A Compositions stabilized with substituted amino carbamates CIBA-GEIGY CORPORATION (US) 1988-07-19 US disclosed
EP-0244355-A2 Compositions stabilized with substituted aminocarbamates, and substituted aminocarbamates CIBA-GEIGY AG (CH) 1987-11-04 EP disclosed